{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-031309","form_type":"8-K","ticker":"CPHI","cik":"0001106644","company_name":"CHINA PHARMA HOLDINGS, INC.","filed_at":"2023-04-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.955724+00:00","generated_at":"2026-06-16T22:11:44.021797+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"China Pharma Holdings extends convertible note maturity to May 2024 with Streeterville Capital","bullets":["Maturity extended from November 2021 note to May 19, 2024, with an extension fee of 2% of the outstanding balance.","Outstanding balance as of April 12, 2023 was $3,281,970.19; original note principal was $5,250,000.","Conversion price reduced to 82% multiplied by the lowest VWAP during the prior 10 trading days.","New monthly redemption minimum of $150,000; failure to meet triggers a 1% penalty increase to outstanding balance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-031309","json":"https://secwatch.observer/filing/0001213900-23-031309.json","markdown":"https://secwatch.observer/filing/0001213900-23-031309.md","text":"https://secwatch.observer/filing/0001213900-23-031309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1106644/000121390023031309/0001213900-23-031309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1106644/000121390023031309/ea177239-8k_chinapharm.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T22:11:44.021797+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4427e13dd6f5c2a4cd665f93d812262b65a6af9c","claim":"CHINA PHARMA HOLDINGS, INC. amended Amendment to Convertible Promissory Note with Streeterville Capital, LLC valued at Extended maturity date to May 19, 2024; extension fee of 2% of outstanding balance; reduced conversi (effective 2023-04-13).","evidence_excerpt":"On April 13, 2023, China Pharma Holdings, Inc. (the “Company”) entered into an Amendment (the “Amendment”), to the Convertible Promissory Note (the “Note”) the Company issued to an institutional accredited investor Streeterville Capital, LLC (“Investor”) pursuant to a Securities Purchase Agreement (the “Agreement”) dated November 17, 2021. The Investor and the Company have agreed, according to the terms of the Amendment, to extend the maturity date of the Note to May 19, 2024. In consideration to the extension, the Company has agreed to pay to the Investor an extension fee equal to two percent (2%) of the outstanding balance of the Note, decrease the price at which the Investor can convert portions of the Note’s outstanding balance to the Company’s common stock, and assume an additional obligation to redeem a portion of the outstanding balance of the Note monthly or be subject to additional penalty fees. The Amendment also includes customary representations and warranties by the Compan","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1106644/000121390023031309/0001213900-23-031309-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"Extended maturity date to May 19, 2024; extension fee of 2% of outstanding balance; reduced conversi"},{"label":"Effective","value":"2023-04-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}